Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Results with ORCHARD cohort of first-line datopotamab deruxtecan (Trop2 ADC) plus osimertinib in EGFR NSCLC Annals of Oncology. At 6mg/kg, RR 36%, PFS 11.7m, DOR 20.5m, OS 26.2m – impressive but 76% G3+ AEs, 59% dose reduced, and ILD seen in 15%.”
Title: Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD
Authors: J.W. Riess, H.A. Yu, X. Le, A. Johannes de Langen, B. Chul Cho, Z. Piotrowska, L.E.L. Hendriks, A. Morabito, L. Bonanno, O. Terje Brustugun, T.O. Halvorsen, Y. Jung Kim, K.A. Marrone, Y. Shiraishi, J.W. Goldman, H. Ambrose, P.E. Smith, P.G. FraenkeI, K. Ho Tang, J.M. Lehman, S.B. Goldberg.
Other articles featuring Stephen V Liu on OncoDaily.